Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

TriSalus Life Sciences, Inc. (TLSI) had Revenue of $11.41M for the most recently reported fiscal quarter, ending 2026-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2026-06-30

Income Statement Financials
Revenue	$11.41M
Net Income	$-9.19M
Cost of Goods Sold	$1.51M
Gross Profit	$9.90M
Operating Expenses	$21.22M
Operating Income	$-9.81M
Non-Operating Income/Expense	$0.63M
Pre-Tax Income	$-9.18M
Normalized Pre-Tax Income	$-9.18M
Income after Taxes	$-9.19M
Income from Continuous Operations	$-9.19M
Consolidated Net Income/Loss	$-9.19M
Normalized Income after Taxes	$-9.19M
EBIT	$-9.81M
EBITDA	$-9.34M
Weighted-Average Shares Outstanding (Basic)	58.30M
Weighted-Average Shares Outstanding (Diluted)	58.30M
Earnings per Share (EPS) (Basic)	$-0.16
Earnings per Share (EPS) (Diluted)	$-0.16
Balance Sheet Financials
Current Assets	$59.74M
Property, Plant, and Equipment	$1.84M
Long-Term Assets	$2.70M
Total Assets	$62.45M
Current Liabilities	$11.17M
Long-Term Debt	$33.06M
Long-Term Liabilities	$44.73M
Total Liabilities	$55.90M
Common Equity	$6.55M
Tangible Shareholders Equity	$6.55M
Shareholders Equity	$6.55M
Common Shares Outstanding	61.47M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-16.61M
Cash Flow from Investing Activities	$-0.22M
Cash Flow from Financial Activities	$42.33M
Beginning Cash	$20.79M
End Cash	$46.29M
Increase/Decrease in Cash	$25.50M
Stock-Based Compensation	$5.09M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.35
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.83
Debt to Equity Ratio	5.05
Gross Margin	86.78%
Operating Margin	-86.03%
EBIT Margin	-86.03%
EBITDA Margin	--
Pre-Tax Profit Margin	-80.50%
Profit Margin	-80.54%
Free Cash Flow	$-16.83M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.18
Inventory Turnover	0.36
Receiveable Turnover	1.77
Days Sales in Receivables	50.96
Return on Equity	-140.26%
Return on Tangible Equity	-140.26%
Return on Assets	-14.71%
Return on Investments	-23.19%
Book Value Per Share	$0.11
Free Cash Flow per Share	$-0.29
Operating Cash Flow per Share	$-0.28

Data from Zacks Investment Research, Inc.